Medicenna Therapeutics Corp.

TSX:MDNA Stock Report

Market Cap: CA$178.7m

Medicenna Therapeutics Management

Management criteria checks 2/4

Medicenna Therapeutics' CEO is Fahar Merchant, appointed in Oct 2011, has a tenure of 12.58 years. total yearly compensation is CA$877.19K, comprised of 48.8% salary and 51.2% bonuses, including company stock and options. directly owns 10.59% of the company’s shares, worth CA$18.92M. The average tenure of the management team and the board of directors is 9.7 years and 2.3 years respectively.

Key information

Fahar Merchant

Chief executive officer

CA$877.2k

Total compensation

CEO salary percentage48.8%
CEO tenure12.6yrs
CEO ownership10.6%
Management average tenure9.7yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28
Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08
Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01
Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

Apr 14
Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Dec 30
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Fahar Merchant's remuneration changed compared to Medicenna Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CA$15m

Sep 30 2023n/an/a

-CA$12m

Jun 30 2023n/an/a

-CA$9m

Mar 31 2023CA$877kCA$428k

-CA$10m

Dec 31 2022n/an/a

-CA$9m

Sep 30 2022n/an/a

-CA$13m

Jun 30 2022n/an/a

-CA$20m

Mar 31 2022CA$894kCA$436k

-CA$23m

Dec 31 2021n/an/a

-CA$25m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$21m

Mar 31 2021CA$868kCA$543k

-CA$17m

Dec 31 2020n/an/a

-CA$14m

Sep 30 2020n/an/a

-CA$11m

Jun 30 2020n/an/a

-CA$9m

Mar 31 2020CA$852kCA$411k

-CA$8m

Dec 31 2019n/an/a

-CA$7m

Sep 30 2019n/an/a

-CA$6m

Jun 30 2019n/an/a

-CA$5m

Mar 31 2019CA$565kCA$375k

-CA$5m

Dec 31 2018n/an/a

-CA$5m

Sep 30 2018n/an/a

-CA$5m

Jun 30 2018n/an/a

-CA$6m

Mar 31 2018CA$907kCA$380k

-CA$7m

Compensation vs Market: Fahar's total compensation ($USD641.22K) is above average for companies of similar size in the Canadian market ($USD175.44K).

Compensation vs Earnings: Fahar's compensation has been consistent with company performance over the past year.

CEO

Fahar Merchant (66 yo)

12.6yrs

Tenure

CA$877,185

Compensation

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...

Leadership Team

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder12.6yrsCA$877.19k10.59%
CA$ 18.9m
Rosemina Merchant
Founder & Chief Development Officer13.1yrsCA$613.71k10.59%
CA$ 18.9m
David Hyman
Chief Financial Officerless than a yearno data0.029%
CA$ 51.3k
Samuel Denmeade
Scientific Advisorno datano datano data

9.7yrs

Average Tenure

66yo

Average Age

Experienced Management: MDNA's management team is seasoned and experienced (9.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder12.6yrsCA$877.19k10.59%
CA$ 18.9m
John Geltosky
Independent Director3.7yrsCA$117.45kno data
Karen Dawes
Independent Director4.7yrsCA$123.70k0.036%
CA$ 64.2k
Albert Beraldo
Lead Independent Director7.5yrsCA$142.95k0.47%
CA$ 834.1k
Lillian Siu
Member of Clinical Advisory Board2.2yrsno datano data
David Mooney
Member of Scientific Advisory Board2.3yrsno datano data
John Sampson
Independent Director2.7yrsCA$111.83kno data
Sergio Quezada
Chairman of Scientific Advisory Board2.3yrsno datano data
Paolo Ascierto
Member of Clinical Advisory Board2.2yrsno datano data
Burkhard Becher
Member of Scientific Advisory Board2.3yrsno datano data
William Redmond
Member of Scientific Advisory Board2.3yrsno datano data
Hussein Tawbi
Member of Clinical Advisory Board2.2yrsno datano data

2.3yrs

Average Tenure

68yo

Average Age

Experienced Board: MDNA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.